# US 8,569,376 B2 · Methods and compositions for reducing body fat and adipocytes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,569,376 B2
- Document ID: US8569376B2
- Status: Granted
- Kind: B2
- Application number: 13/782,659
- Filed: 2013-03-01
- Published: 2013-07-11
- Granted: 2013-10-29
- Earliest claimed: 2011-12-19
- Assignees: Topokine Therapeutics, Inc.
- Applicants: Topokine Therapeutics, Inc.
- Inventors: Murat V. Kalayoglu; Michael S. Singer
- Web page: https://patentgrep.com/patent/US8569376B2

## CPC

- A61K 31/5575: having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
- A61K 8/69: containing fluorine
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 31/165: having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K 31/191: having two or more hydroxy groups, e.g. gluconic acid
- A61K 31/216: of acids having aromatic rings, e.g. benactizyne, clofibrate
- A61K 31/25: with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61Q 19/005: {Preparations for sensitive skin}
- A61Q 19/06: for countering cellulitis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS

## Abstract

Provided are methods of reducing body fat in a subject, comprising locally (e.g., topically) administering one or more compounds of the Formula (I) and/or (V): or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, polymorph, tautomer, isotopically enriched derivative, or prodrug thereof, wherein X is —OR1, —SR2, or —NR3R4, and R1, R2, R3, R4, R5, R6, R7, R7′, Z, Y, n, y, and x, are as defined herein.

## Claims

### Claim 1

A method for reducing fat in a body of a subject in need thereof, the method comprising administering to the skin of the subject a composition comprising a compound of the Formula (II):
or a pharmaceutically acceptable salt or stereoisomer thereof, and one or more pharmaceutically acceptable excipients;
wherein R1 is hydrogen or; and wherein the composition comprises about 0.001% to about 1% (w/w) or (w/v), inclusive, of the compound C1-6 alkyl.

### Claim 2 (depends on 1)

The method of claim 1, wherein R1 is hydrogen.

### Claim 3 (depends on 1)

The method of claim 1, wherein R1 is C1-C4 alkyl.

### Claim 4 (depends on 1)

The method of claim 1, wherein R1 is methyl, ethyl, isopropyl, n-propyl, n-butyl, tert-butyl, isobutyl, or sec-butyl.

### Claim 5 (depends on 1)

The method of claim 1, wherein R1 is ethyl.

### Claim 6 (depends on 1)

The method of claim 1, wherein R1 is isopropyl.

### Claim 7 (depends on 1)

The method of claim 1, wherein the subject suffers from obesity.

### Claim 8 (depends on 1)

The method of claim 1, wherein the subject suffers from gynecomastia.

### Claim 9 (depends on 1)

The method of claim 1, wherein the subject suffers from HIV lipodystrophy.

### Claim 10 (depends on 1)

The method of claim 1, wherein the subject suffers from lipoma.

### Claim 11 (depends on 1)

The method of claim 1, wherein the subject suffers from excess fat on the chin.

### Claim 12 (depends on 1)

The method of claim 1, wherein the subject suffers from orbital fat prolapse.

### Claim 13 (depends on 1)

The method of claim 1, wherein the step of administering comprises topical administration.

### Claim 14 (depends on 1)

The method of claim 1, wherein the step of administering comprises subcutaneous, intradermal, or intralesional administration.

### Claim 15 (depends on 1)

The method of claim 1, wherein the step of administering to the skin of subject comprising administering to the skin of a body part selected from the group consisting of the abdomen, chest, breast, buttocks, hips, thighs, legs, knees, arms, chin, neck, and face.